Abemaciclib is a selective inhibitor of cyclin-dependent kinases 4 and 6, used for HR-positive, HER2-negative breast cancer. It helps slow down cancer cell proliferation and improve survival rates. It is grouped under the following drug class(es): Antineoplastic agents, CDK4/6 Inhibitors and Kinase inhibitors. Its therapeutic use is listed as anti-cancer agents and antineoplastics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Verzenio, Verzenios and abemaciclibum. Its PubChem CID is 46220502.
Abemaciclib
| CAS No | 1231929-97-7 |
|---|---|
| Molecular Formula | C27H32F2N8 |
| Molecular Weight | 506.56 g/mol |
| Synonyms | N-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Abemaciclib is a selective inhibitor of cyclin-dependent kinases 4 and 6, used for HR-positive, HER2-negative breast cancer. It helps slow down cancer cell proliferation and improve survival rates.
The listed CAS number is 1231929-97-7.
The listed molecular formula is C27H32F2N8.
The listed molecular weight is 506.56 g/mol.
N-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine.
The source lists Verzenio, Verzenios and abemaciclibum.